SpotitEarly announced a research partnership with Hackensack Meridian Health to launch the PINK Study, a 2,000-participant U.S. clinical trial focused on breath-based breast-cancer screening.
The study will validate SpotitEarly’s LUCID AI platform and detection-dog methodology in collaboration with the Hennessy Institute for Cancer Prevention.

SpotitEarly announced its formal entry into the U.S. market, backed by more than $20 million in new funding to advance its at-home breath-based cancer detection platform.
The company detailed plans to expand operations, partner with U.S. health systems, and continue developing its AI + canine technology for large-scale screening.

SpotitEarly announced breakthrough results from its multicancer “Rainbow Study,” showing that its breath-based test combining trained dogs and AI can detect cancers such as breast, lung, prostate, and colorectal with over 94% accuracy. The study involved more than 1,400 participants and demonstrated strong performance even at early stages (0-II).